516526-43-5

Basic information

• Product Name: Quinoline, 4-chloro-7-methoxy-6-(phenylmethoxy)-
• CAS NO: 516526-43-5
• Molecular Formula: C17H14ClNO2
• Molecular Weight: 299.757
• Mol File: 516526-43-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Quinoline, 4-chloro-7-methoxy-6-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoline, 4-chloro-7-methoxy-6-(phenylmethoxy)-(516526-43-5)
• EPA Substance Registry System: Quinoline, 4-chloro-7-methoxy-6-(phenylmethoxy)-(516526-43-5)

Safety Data

• Hazardous Substances Data: 516526-43-5(Hazardous Substances Data)

Upstream product

• 205448-74-4 4-chloro-7-methoxyquinolin-6-ol 
• 100-39-0 benzyl bromide 
• 516526-40-2 1‐(5‐(benzyloxy)‐4‐methoxy‐2‐nitrophenyl)ethanone 
• 23428-77-5 1‐(3‐(benzyloxy)‐4‐methoxyphenyl)ethanone 
• 6100-74-9 3-hydroxy-4-methoxyacetophenone 
• 67851-29-0 2-methoxy-4-nitrophenyl acetate 
• 71573-23-4 4-amino-2-methoxyphenyl acetate 
• 3251-56-7 2-methoxy-4-nitrophenol 
• 205448-73-3 acetic acid 4-[(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylidenemethyl)-amino]-2-methoxy-phenyl ester 
• 914490-28-1 acetic acid 7-methoxy-4-oxo-1,4-dihydro-quinolin-6-yl ester 
• 516526-42-4 6-benzyloxy-7-methoxy-1H-quinolin-4-one 

Downstream Products

• 516526-46-8 6-benzyloxy-4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline 
• 1292259-33-6 2-{4-[2-fluoro-4-(2-trifluoromethylbenzenesulfonylamino)phenoxy]-6-methoxyquinolin-7-yloxy}-N,N-dimethylacetamide 
• 516526-45-7 4-(2-fluoro-4-nitrophenoxy)-7-methoxylquinolyl-6-ol 
• 1292259-19-8 N-(3-fluoro-4-{7-methoxy-6-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)-2-trifluoromethylbenzenesulfonamide 
• 914490-30-5 N-[4-(6-hydroxy-7-methoxy-quinolin-4-yloxy)-phenyl]-benzamide 
• 1149370-99-9 7-(6-(benzyloxy)-7-methoxyquinolin-4-yloxy)-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 914490-29-2 N-[4-(6-benzyloxy-7-methoxy-quinolin-4-yloxy)-phenyl]-benzamide 

Relevant articles and documents

Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer

In this investigation, a novel series of quinoline analogues bearing thiazolidinones were designed and synthesized based on our previous study. Among them, the most potent compound 11k, 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)phen

QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY

Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y1, L1 and z are as defined in the claims; R6 is C1-C4alkoxy, hydrogen or halo; W represents a bond, -CH2-, -O-, -S-, -S(=O)2-, or -NR5- where R5 is hydrogen or C1-C4 alkyl; Q is =N-, =CH- or =C(X1)- wherein X1 is cyano, cyclopropyl or halo; linker radicals L2 are as defined in the claims; R is a radical of formula (X) or (Y): wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, heteroaryl(C1-C6 alkyl)-, -(C=O)R3, -(C=O)OR3, or -(C=O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, or heteroaryl(C1-C6 alkyl)-; R41 is hydrogen or optionally substituted C1-C6 alkyl; and D is a monocyclic heterocyclic ring of 5 or 6 ring atoms.

QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME

An objective of the present invention is to provide compounds and pharmaceticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R1, R2, and R3 represent H, OH, or optionally substituted alkoxy; R4 represents H; R5, R6, R7, and R8 represent H, Hal, alkyl or the like; and R9 represents, e.g., alkyl substituted by t-butyl or the like.